If you are searching fisetin side effects, the most accurate starting point is this: human safety evidence exists, but it is still limited, short-term, and incomplete. A few human studies and trial records suggest that fisetin has sometimes been tolerated without major short-term safety signals, but the published dataset is small, interaction studies are sparse, and absence of reported problems does not prove long-term safety or compatibility with medications. PubMed PMID 36304817 PubMed PMID 39269340 NCCIH
For dose context, see the main fisetin dosage research summary. For the human-trial overview, see the fisetin clinical trials index.
What human studies report about fisetin side effects
The clearest published human safety details come from a 2022 randomized crossover pharmacokinetic study in healthy volunteers. According to the paper, there were no significant adverse events or clinical signs attributed to fisetin supplementation, but two minor gastrointestinal complaints were reported: one bloating sensation and one decrease in appetite. These occurred with both unformulated fisetin and the enhanced-bioavailability formulation used in the study. PubMed PMID 36304817 PMC article
A second often-cited human study is the 2024 pilot study in healthy adults over age 50. It used 500 mg daily for one week per month for six months and reported that no adverse effects were noted among the ten participants. That is useful as an early signal, but it remains a very small pilot study. PubMed PMID 39269340
Beyond those papers, several ClinicalTrials.gov records show fisetin being tested with explicit safety and tolerability monitoring in older adults, frailty, vascular-function, COVID-19, and other contexts. But for many of these studies, peer-reviewed adverse-event analyses are still limited or unavailable. So the best summary of current fisetin supplement side effects evidence is narrow: minor GI complaints have been reported in one PK study; a tiny pilot reported no adverse effects; broader safety remains under study. ClinicalTrials.gov: NCT07195318 ClinicalTrials.gov: NCT06133634
Why absence of reported effects does not prove long-term safety
This is one of the most important distinctions in any fisetin safety article. "No adverse effects reported" is not the same as "proven safe."
Small studies can miss uncommon side effects. Short studies can miss delayed side effects. Selected study populations can miss risks that matter in real-world users with comorbidities or multiple medications. And trial formulations may not match commercial products exactly. NCCIH and FDA both emphasize that dietary supplements may interact with medications, may pose problems in people with medical conditions, and may present special concerns around surgery, pregnancy, and other clinical situations. NCCIH FDA
The healthy-aging fisetin trial record itself notes that evidence for beneficial effects, effective doses, and safety profiles in humans is still extremely limited, and that supplement quality and actual content may vary. That means fisetin should be discussed as an early-evidence supplement, not a safety-settled one. ClinicalTrials.gov: NCT07195318
Possible dose-related concerns
Human fisetin studies use very different dose formats and schedules: single 1000 mg pharmacokinetic exposures, 500 mg daily monthly pulse blocks, 100 mg daily low-dose trials, and 20 mg/kg/day short senolytic-style protocols. That alone suggests that dose-related risk cannot be simplified to one number. PubMed PMID 36304817 PubMed PMID 39269340 ClinicalTrials.gov: NCT06431932
A larger amount taken once in a monitored PK study is not the same as repeated self-use. A short 2-day weight-based pulse is not the same as ongoing daily supplementation. And a fixed 100 mg label dose is not directly comparable with a weight-based 20 mg/kg protocol. That is why current evidence does not support a confident statement about a "safe" fisetin maximum dose for routine use.
Potential interaction categories
A careful way to think about fisetin drug interactions is to separate what is actually documented from what is theoretical or still unknown.
| Category | Current evidence level | What can be said cautiously |
|---|---|---|
| Documented human evidence | Limited | Published fisetin studies report little short-term toxicity, with minor GI complaints in one PK study and no adverse effects noted in one 10-person pilot. |
| Theoretical interaction | Moderate concern, low fisetin-specific proof | Trials exclude many medications, and FDA/NCCIH warn that dietary supplements can alter drug absorption, metabolism, bleeding risk, or surgical safety. |
| Animal or laboratory evidence | Mechanistic only | Preclinical fisetin data may suggest biological activity, but they do not confirm real-world human interactions. |
| Unknown risk | High | Long-term combination use with anticoagulants, diabetes drugs, chemotherapy, or perioperative medications has not been well characterized in dedicated fisetin interaction trials. |
This distinction matters because readers often see phrases like fisetin contraindications or who should not take fisetin and expect hard yes-or-no rules. In reality, many of the strongest warnings come from the combination of limited direct evidence plus general supplement-interaction principles plus trial exclusion criteria.
Fisetin and anticoagulant or antiplatelet medication
There is not strong human evidence proving that fisetin definitely causes bleeding or definitively interacts with blood thinners. But there are enough caution signals that this category should not be treated casually.
First, MedlinePlus explains that blood thinners interact with medicines, vitamins, and supplements, and that bleeding is their main serious side effect. It specifically advises making sure health care providers know about all medicines and supplements being used. MedlinePlus
Second, MedlinePlus' warfarin monograph warns that supplements and herbal products may increase bleeding risk and emphasizes reporting all supplements to clinicians. MedlinePlus Warfarin
Third, fisetin trials themselves often exclude anticoagulant-related situations. The AFFIRM trial in older women excluded subjects on therapeutic anticoagulants such as warfarin, heparin, low-molecular-weight heparin, and factor Xa inhibitors, and also listed additional antiplatelet or related medications among drugs of concern. The COVID outpatient fisetin trial excluded participants on warfarin. These exclusions do not prove a confirmed fisetin interaction, but they clearly show that investigators treated anticoagulation and bleeding risk as clinically relevant concerns. ClinicalTrials.gov: NCT03430037 ClinicalTrials.gov: NCT04771611
So for the search term fisetin and blood thinners, the evidence-based answer is: no confirmed human fisetin–warfarin interaction has been established in the sources reviewed here, but trials and government sources support caution, not reassurance.
Fisetin and diabetes medication
Direct human fisetin–diabetes-drug interaction evidence is very limited. However, fisetin trials in older adults do flag diabetes medication as a concern. The AFFIRM trial excluded diabetic participants using sulfonylureas, SGLT2 inhibitors, or insulin. That does not prove fisetin has a dangerous interaction with those drugs. But it does show that trial investigators did not consider these medication contexts routine enough to include without restriction. ClinicalTrials.gov: NCT03430037
There is also a more general surgical and medical-management principle here: MedlinePlus notes that some diabetic and weight-loss medications may need to be managed differently around surgery, and NCCIH/FDA both warn that supplements can alter medication effects. So for people on diabetes treatment, the current evidence supports medical review before use, not a claim of compatibility. MedlinePlus pre-surgery guidance FDA
Fisetin and cancer treatment
There is no solid human evidence from the sources reviewed here proving that fisetin safely combines with chemotherapy or targeted cancer therapy in routine practice. In fact, some trial records move in the opposite direction and suggest caution.
The COVID fisetin trial excluded patients undergoing chemotherapy for cancer. AFFIRM-LITE excluded tyrosine kinase inhibitor therapy and many drugs with narrow interaction or metabolism concerns. Meanwhile, the breast-cancer survivorship fisetin trials are not examples of casual supplement use during active cancer therapy; they are structured, monitored research protocols in defined survivorship populations. ClinicalTrials.gov: NCT04771611 ClinicalTrials.gov: NCT03675724 ClinicalTrials.gov: NCT05595499
So the safest evidence-based formulation is this: no confirmed broad fisetin-oncology interaction rule is established, but fisetin should not be assumed compatible with active cancer treatment merely because it is "natural."
Fisetin before surgery
This is one of the clearest areas where government medical guidance matters even without fisetin-specific surgery trials.
NCCIH states that some dietary supplements may cause problems during surgery because they can affect anesthesia response, increase bleeding risk, or cause significant heart-rate or blood-pressure changes. It notes that some health care providers ask patients to discontinue all herbal supplements several weeks before elective surgery. NCCIH
MedlinePlus advises patients not to take supplements, herbs, vitamins, or minerals before surgery unless the surgeon says it is okay. MedlinePlus pre-surgery guidance
FDA also warns that some supplements can interact harmfully with medications needed before, during, or after surgery, including by changing bleeding risk, blood pressure, or heart rate. FDA
So for the search term fisetin before surgery, the safest medically cautious answer is: there is not enough fisetin-specific perioperative evidence to assume safety, and general government guidance supports stopping or reviewing supplements with the surgical team in advance.
Pregnancy, breastfeeding, and younger users
There is no robust human evidence establishing fisetin safety in pregnancy, breastfeeding, or children.
MedlinePlus advises pregnant patients to check with their provider before starting or stopping any medicine, including dietary or herbal supplements. MedlinePlus Pregnancy
NCCIH states more broadly that many dietary supplements have not been tested in pregnant women, nursing mothers, or children. NCCIH
This lack of evidence is reflected in fisetin trials themselves. Pregnancy and breastfeeding commonly appear as exclusion criteria in clinical studies, including COVID and osteoarthritis protocols. That means fisetin has unknown risk, not demonstrated safety, in these groups. ClinicalTrials.gov: NCT04771611 ClinicalTrials.gov: NCT04770064
Liver and kidney conditions
Human fisetin trials repeatedly exclude significant liver or kidney impairment. That is a practical sign that safety in these groups is not established.
The COVID trial excluded severe hepatic disease and very elevated liver enzymes. AFFIRM excluded significant liver or renal disease. AFFIRM-LITE excluded participants with abnormal liver-related and kidney-related screening findings and severe renal impairment. These exclusions do not prove fisetin causes liver or kidney injury. But they do mean fisetin has not been adequately established as safe in these populations. ClinicalTrials.gov: NCT04771611 ClinicalTrials.gov: NCT03430037 ClinicalTrials.gov: NCT03675724
NCCIH also notes that dietary supplements can pose risks in people with certain medical problems and that acute liver injury from supplements, while still uncommon overall, is a recognized issue in the supplement world more broadly. That is general supplement safety context, not a fisetin-specific injury signal, but it supports caution in people with pre-existing liver disease. NCCIH
When to stop and seek medical advice
NCCIH advises stopping a supplement and contacting a health care provider if side effects occur. NCCIH
In practical terms, urgent medical review is appropriate if symptoms raise concern for bleeding, allergic reaction, organ dysfunction, or severe intolerance. Examples include unusual bruising, bleeding that does not stop, black or bloody stools, red or brown urine, vomiting blood or coffee-ground material, yellowing of the skin or eyes, severe abdominal pain, shortness of breath, swelling of the face or throat, marked dizziness, or a major worsening in condition. These warning signs come partly from general anticoagulant and supplement-safety guidance, not from confirmed fisetin-specific toxicity rules, but they are still clinically important red flags. MedlinePlus Blood Thinners MedlinePlus Warfarin
Evidence snapshot by risk type
| Risk type | Best-supported status |
|---|---|
| Documented human evidence | Minor GI complaints reported in one fisetin PK study; no adverse effects noted in one 10-person pilot |
| Theoretical interaction | Drug-metabolism interactions, bleeding-risk concerns, perioperative concerns, additive medication effects |
| Animal or laboratory evidence | Mechanistic only; not enough to confirm a clinical interaction |
| Unknown risk | Pregnancy, breastfeeding, children, chronic use with blood thinners, active chemotherapy, major liver/kidney impairment, perioperative use without clinician guidance |
FAQ
What side effects have actually been reported in human fisetin studies?
Published human data are limited. One healthy-volunteer PK study reported no significant adverse events, with two minor GI complaints: bloating and decreased appetite. A small 2024 pilot reported no adverse effects in ten subjects. PubMed PMID 36304817 PubMed PMID 39269340
Does fisetin have proven drug interactions?
Not many confirmed fisetin-specific interactions have been established in direct human studies. Most current concerns are based on trial exclusions, supplement-interaction principles, and the lack of dedicated interaction trials.
Who should not take fisetin?
The evidence is not strong enough to create a universal prohibition list, but groups that warrant medical review before use include people on blood thinners, those using diabetes or cancer medications, those with liver or kidney disease, anyone pregnant or breastfeeding, younger users, and people preparing for surgery.
Is fisetin and blood thinners a confirmed dangerous interaction?
A confirmed fisetin-specific human interaction has not been established in the sources reviewed here. But anticoagulant use was excluded from fisetin trials, and government sources warn that supplements can raise bleeding concerns with blood thinners. ClinicalTrials.gov: NCT03430037 MedlinePlus
Should fisetin be stopped before surgery?
General government guidance says supplements should be discussed with the surgical team in advance, and many should be stopped unless the surgeon approves them. That cautious approach is appropriate for fisetin because perioperative fisetin safety is not established. MedlinePlus pre-surgery guidance NCCIH
Is fisetin safe in pregnancy?
Human pregnancy safety has not been established. Government guidance advises checking with a provider before using herbal or dietary supplements during pregnancy. MedlinePlus Pregnancy
Are fisetin contraindications officially established?
Not in the way prescription-drug contraindications are. Most current "contraindication-like" concerns come from exclusion criteria, uncertainty, and general supplement-interaction principles.
Does fisetin harm the liver or kidneys?
There is no strong human proof from the reviewed sources that fisetin directly causes liver or kidney injury, but trials often excluded significant liver or kidney disease, so safety in those groups is not established. ClinicalTrials.gov: NCT04771611 ClinicalTrials.gov: NCT03430037
Is absence of side effects in a study enough to prove safety?
No. Small or short studies can miss uncommon, delayed, or population-specific harms.
What should I do if I get side effects after taking fisetin?
Stop the supplement and contact a health care provider. Seek urgent care for serious bleeding, allergic symptoms, jaundice, major weakness, or other severe warning signs. NCCIH
Bottom line
The most evidence-based conclusion about fisetin side effects is a cautious one. Human data do not currently show a large, well-defined side-effect profile, but they also do not prove that fisetin is interaction-free or broadly safe across medications and medical conditions. Right now, the strongest direct human evidence suggests only limited short-term tolerability information, while the strongest reasons for caution come from trial exclusions, general government guidance on supplement–drug interactions, and large gaps in long-term safety evidence. PubMed PMID 36304817 PubMed PMID 39269340 NCCIH FDA
So if someone asks who should not take fisetin, the honest answer is not a simple blacklist. It is this: the more medically complex the situation, the less appropriate it is to assume safety without clinical review.
This article is intended for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making significant changes to your diet, exercise routine, or supplement regimen, especially if you have an existing medical condition, are pregnant or breastfeeding, or take prescription medications.